Morgan Stanley Avadel Pharmaceuticals PLC Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Oct 17, 2024	BUY	$12.55 - $17.22 $8.35 Million - $11.5 Million	665,411 New	665,411 $11.2 Million
Q1 2024 Aug 16, 2024	SELL	$12.55 - $17.22 $4.1 Million - $5.62 Million	-326,586 Reduced 32.92%	665,411 $11.2 Million
Q1 2024 May 15, 2024	SELL	$12.55 - $17.22 $4.1 Million - $5.62 Million	-326,586 Reduced 32.92%	665,411 $11.2 Million
Q4 2023 Aug 16, 2024	BUY	$9.64 - $14.59 $9.56 Million - $14.5 Million	991,997 New	991,997 $14 Million
Q4 2023 Feb 13, 2024	BUY	$9.64 - $14.59 $5.35 Million - $8.1 Million	554,941 Added 126.97%	991,997 $14 Million
Q3 2023 Nov 15, 2023	SELL	$10.3 - $15.99 $247,591 - $384,367	-24,038 Reduced 5.21%	437,056 $4.5 Million
Q2 2023 Aug 14, 2023	BUY	$8.48 - $16.48 $978,447 - $1.9 Million	115,383 Added 33.38%	461,094 $7.6 Million
Q1 2023 May 15, 2023	SELL	$6.41 - $9.95 $10,313 - $16,009	-1,609 Reduced 0.46%	345,711 $3.17 Million
Q4 2022 Feb 14, 2023	BUY	$5.02 - $10.0 $2,349 - $4,680	468 Added 0.13%	347,320 $2.49 Million
Q3 2022 Nov 14, 2022	BUY	$2.57 - $7.31 $78,361 - $222,889	30,491 Added 9.64%	346,852 $1.74 Million
Q2 2022 Oct 27, 2022	SELL	$1.07 - $6.95 $28,513 - $185,203	-26,648 Reduced 7.77%	316,361 $772,000
Q2 2022 Aug 15, 2022	SELL	$1.07 - $6.95 $28,513 - $185,203	-26,648 Reduced 7.77%	316,361 $772,000
Q1 2022 Oct 27, 2022	BUY	$5.46 - $8.29 $145,498 - $220,911	26,648 Added 8.42%	343,009 $2.34 Million
Q1 2022 May 13, 2022	SELL	$5.46 - $8.29 $623,832 - $947,173	-114,255 Reduced 24.99%	343,009 $2.34 Million
Q4 2021 Feb 14, 2022	BUY	$7.34 - $11.18 $242,542 - $369,431	33,044 Added 7.79%	457,264 $3.69 Million
Q3 2021 Nov 15, 2021	BUY	$6.49 - $9.91 $2.75 Million - $4.2 Million	424,220 New	424,220 $4.16 Million

Others Institutions Holding AVDL

# of Institutions

Shares Held

1.07M

Call Options Held

Put Options Held

View Full List

About AVADEL PHARMACEUTICALS PLC

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

More about AVDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account